Health State Utilities Associated With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Author(s)
Louis Matza, PhD1, Katie D. Stewart, MA1, He Guo, MPP, MSc2, Chris Ridley, BSc, MSc, PhD3, Maria Mata Lorenzo, MSc3, Stephanie H Y Lee, PhD4, Michael Mbagwu, MD2, Priti Patel, BSc5, Simon Matthews, BA5, David Burton, PhD5, Laura Cunliffe, BA5, Scott Doyle, PhD3.
1Thermo Fisher Scientific, PPD Evidera Solutions, Waltham, MA, USA, 2Astellas Pharma Inc., Northbrook, IL, USA, 3Astellas Pharma Europe Ltd., Addlestone, United Kingdom, 4Astellas Pharma Singapore Ltd., Singapore, Singapore, 5Lucid Group Communications Ltd, London, United Kingdom.
1Thermo Fisher Scientific, PPD Evidera Solutions, Waltham, MA, USA, 2Astellas Pharma Inc., Northbrook, IL, USA, 3Astellas Pharma Europe Ltd., Addlestone, United Kingdom, 4Astellas Pharma Singapore Ltd., Singapore, Singapore, 5Lucid Group Communications Ltd, London, United Kingdom.
OBJECTIVES: Geographic atrophy (GA) secondary to age-related macular degeneration can cause irreversible vision loss. New treatments have been developed that slow the progression of GA, and health state utilities (i.e., preference weights representing QoL) are needed for cost-utility analyses examining their value. This study aimed to estimate health state utilities specifically associated with GA.
METHODS: Seven health state vignettes with varying GA severity were developed based on literature review, input from clinical experts, interviews with patients with GA, and interviews with patients’ caregivers. Vignettes included a description of the GA lesion size (i.e., area), distance of the lesion to the foveal center, impact on QoL, and an image simulating visual impairment associated with the lesion. Health states were valued in time trade-off interviews with general population respondents in the UK (Edinburgh and London). Prior to reviewing and valuing health states, each respondent viewed a virtual reality demonstration (with eye movement tracking) that simulated engaging in daily activities with GA lesions of various sizes and distances from the foveal center.
RESULTS: A total of 234 participants completed interviews (51.3% female; 83.3% White; mean age = 46.9 years). Participants preferred health states (as indicated by higher mean utilities) with smaller GA lesions and lesions further from the foveal center. Mean (SD) utilities ranged from 0.88 (0.11) for the mildest health state (small lesion far from the foveal center) to 0.39 (0.44) for a health state with a large lesion covering the central visual area.
CONCLUSIONS: In this general population utility study, health states representative of early GA (smaller GA area and lesions far from the foveal center) were preferred and had higher mean utilities than those representative of advanced GA (larger GA area and lesions near the foveal center). The utilities estimated may be useful for cost-effectiveness models of GA treatment.
METHODS: Seven health state vignettes with varying GA severity were developed based on literature review, input from clinical experts, interviews with patients with GA, and interviews with patients’ caregivers. Vignettes included a description of the GA lesion size (i.e., area), distance of the lesion to the foveal center, impact on QoL, and an image simulating visual impairment associated with the lesion. Health states were valued in time trade-off interviews with general population respondents in the UK (Edinburgh and London). Prior to reviewing and valuing health states, each respondent viewed a virtual reality demonstration (with eye movement tracking) that simulated engaging in daily activities with GA lesions of various sizes and distances from the foveal center.
RESULTS: A total of 234 participants completed interviews (51.3% female; 83.3% White; mean age = 46.9 years). Participants preferred health states (as indicated by higher mean utilities) with smaller GA lesions and lesions further from the foveal center. Mean (SD) utilities ranged from 0.88 (0.11) for the mildest health state (small lesion far from the foveal center) to 0.39 (0.44) for a health state with a large lesion covering the central visual area.
CONCLUSIONS: In this general population utility study, health states representative of early GA (smaller GA area and lesions far from the foveal center) were preferred and had higher mean utilities than those representative of advanced GA (larger GA area and lesions near the foveal center). The utilities estimated may be useful for cost-effectiveness models of GA treatment.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR108
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)